<DOC>
	<DOCNO>NCT02582983</DOCNO>
	<brief_summary>This study assess safety tolerability enfuvirtide participant advanced HIV genotype 1 ( HIV-1 ) disease . Eligible participant fail treatment regimen contain least one product anti-retroviral class , experience intolerance previous anti-retroviral regimen receive enfuvirtide , 90 milligram ( mg ) subcutaneously ( SC ) twice daily ( BID ) long enfuvirtide related treatment limit toxicity participant benefit study treatment per investigator 's discretion . The anticipated time study treatment base commercial availability enfuvirtide Thailand , target sample size 30 individual .</brief_summary>
	<brief_title>A Study Enfuvirtide ( Fuzeon ) Participants With Advanced Human Immunodeficiency Virus ( HIV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Individuals least 16 year age infect HIV1 CD4 lymphocyte count less equal ( &lt; = ) 100 cell per cubic millimeter ( cells/mm^3 ) HIV1 ribonucleic acid ( RNA ) viral load great equal ( &gt; = ) 10,000 copies/mL highly active antiretroviral therapy ( HAART ) Genotypic phenotypic resistance and/or treatmentlimiting toxicity previous antiretroviral regimen Evidence ongoing alcohol and/or drug substance abuse Prior nonadherence antiretroviral treatment regimen Evidence active , untreated opportunistic infection , intercurrent illness , drug toxicity condition .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>